*banner
 

An ODE Model for the HER2/3-AKT Signaling Pathway in Cancers that Overexpress HER2
Sleiman Itani, J Gray, Claire Tomlin

Citation
Sleiman Itani, J Gray, Claire Tomlin. "An ODE Model for the HER2/3-AKT Signaling Pathway in Cancers that Overexpress HER2". American Control Conference (ACC), 30, July, 2010.

Abstract
Targeted drug therapies have proven very useful as cancer treatments, but some still demonstrate very little antitumor activity in certain cancers. A class of tyrosine kinase inhibitors (TKIs) that are unexpectedly inefficient in some cancers are those that target the human epidermal growth factor receptor (HER) family. This paper proposes a mathematical model of the HER signaling pathway for the study and treatment of cancers that overexpress. The goals of this paper are threefold. The first is to introduce an ODE model that agrees with the existing data over large time intervals, and the second is to use this model to understand the effects of applying certain drugs to such cancers. We finally use this model to determine a “steering-based” treatment scheme for cancers that overexpress HER2.

Electronic downloads

Citation formats  
  • HTML
    Sleiman Itani, J Gray, Claire Tomlin. <a
    href="http://chess.eecs.berkeley.edu/pubs/782.html"
    >An ODE Model for the HER2/3-AKT Signaling Pathway in
    Cancers that Overexpress HER2</a>, American Control
    Conference (ACC), 30, July, 2010.
  • Plain text
    Sleiman Itani, J Gray, Claire Tomlin. "An ODE Model for
    the HER2/3-AKT Signaling Pathway in Cancers that Overexpress
    HER2". American Control Conference (ACC), 30, July,
    2010.
  • BibTeX
    @inproceedings{ItaniGrayTomlin10_ODEModelForHER23AKTSignalingPathwayInCancersThatOverexpress,
        author = {Sleiman Itani and J Gray and Claire Tomlin},
        title = {An ODE Model for the HER2/3-AKT Signaling Pathway
                  in Cancers that Overexpress HER2},
        booktitle = {American Control Conference (ACC)},
        day = {30},
        month = {July},
        year = {2010},
        abstract = {Targeted drug therapies have proven very useful as
                  cancer treatments, but some still demonstrate very
                  little antitumor activity in certain cancers. A
                  class of tyrosine kinase inhibitors (TKIs) that
                  are unexpectedly inefficient in some cancers are
                  those that target the human epidermal growth
                  factor receptor (HER) family. This paper proposes
                  a mathematical model of the HER signaling pathway
                  for the study and treatment of cancers that
                  overexpress. The goals of this paper are
                  threefold. The first is to introduce an ODE model
                  that agrees with the existing data over large time
                  intervals, and the second is to use this model to
                  understand the effects of applying certain drugs
                  to such cancers. We finally use this model to
                  determine a âsteering-basedâ treatment scheme
                  for cancers that overexpress HER2.},
        URL = {http://chess.eecs.berkeley.edu/pubs/782.html}
    }
    

Posted by Christopher Brooks on 24 Nov 2010.
For additional information, see the Publications FAQ or contact webmaster at chess eecs berkeley edu.

Notice: This material is presented to ensure timely dissemination of scholarly and technical work. Copyright and all rights therein are retained by authors or by other copyright holders. All persons copying this information are expected to adhere to the terms and constraints invoked by each author's copyright.

You are not logged in 
©2002-2017 Chess